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Abstract. The Epstein-Barr virus (EBV) is associated with 
a large spectrum of lymphoproliferative diseases. Traditional 
methods of EBV detection include the immunohistochemical 
identification of viral proteins and DNA probes to the viral 
genome in tumoral tissue. The present study explored the 
detection of the EBV genome, using the BALF5 gene, in the 
bone marrow or blood mononuclear cells of patients with 
diffuse large B-cell lymphomas (DLBCL) and related its 
presence to the clinical variables and risk factors. The results 
show that EBV detection in 21.5% of patients is not associated 
with age, gender, staging, B symptoms, international prog-
nostic index scores or any analytical parameters, including 
lactate dehydrogenase (LDH) or β-2 microglobulin (B2M). 
The majority of patients were treated with R-CHOP-like 
(rituximab, cyclophosphamide, doxorubicin, vincristine and 
prednisolone or an equivalent combination) and some with 
CHOP-like chemotherapy. Response rates [complete response 
(CR) + partial response (PR)] were not significantly different 
between EBV-negative and -positive cases, with 93.2 and 
88.9%, respectively. The survival rate was also similar in the 
two groups, with 5-year overall survival (OS) rates of 64.3 and 
76.7%, respectively. However, when analyzing the treatment 
groups separately there was a trend in EBV-positive patients for 
a worse prognosis in patients treated with CHOP-like regimens 
that was not identified in patients treated with R-CHOP-like 
regimens. We conclude that EBV detection in the bone marrow 
and blood mononuclear cells of DLBC patients has the same 
frequency of EBV detection on tumoral lymphoma tissue 
but is not associated with the risk factors, response rate and 
survival in patients treated mainly with immunochemotherapy 
plus rituximab. These results also suggest that the addition of 
rituximab to chemotherapy improves the prognosis associated 
with EBV detection in DLBCL.
Introduction
The Epstein-Barr virus (EBV) belongs to the herpes virus 
family and infects more than 90% of the human population (1). 
It is associated with the development of lymphoid tumors 
and probably also with epithelial neoplasms. EBV colonizes 
B cells and can persist as a life-long asymptomatic infection. 
It has been implicated as the causative agent in a number of 
lymphoproliferative diseases, including Burkitt's lymphoma, 
Hodgkin's lymphoma, plasmablastic lymphoma, certain diffuse 
large B-cell lymphomas (DLBCL) and sub-types of peripheral 
T-cell lymphomas, including natural killer/T-cell lymphomas, 
angioimmunoblastic and lymphomatoid granulomatosis (2-4). 
EBV has also been associated with immunodeficient states 
such as post-transplant lymphoproliferative disorders (LPDs) 
and human immunodeficiency virus (HIV)/acquired immu-
nodeficiency syndrome (AIDS)-associated lymphomas (5,6). 
‘EBV-positive diffuse large B-cell lymphoma of the elderly’ 
has been recognized as a provisional entity of DLBCL. This 
association was initially described by Oyama et al in patients 
predominantly older than 50; however, it has also been docu-
mented in younger patients without immunodeficiency (7).
There is presently substantial evidence supporting the 
etiological role of EBV in cancer. In vitro, the virus trans-
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forms resting B cells into a lymphoblastoid cell line; in vivo, 
EBV-infected cells do not mature to become a resting memory 
cell as they are unable to exit the cell cycle. When T-cell 
function that usually plays a determinant role in controlling 
EBV-associated lymphoproliferative disease is blocked by 
immunosuppressive agents or by HIV infection, there is an 
increased risk of EBV-positive B-cell LPDs (2,6).
EBV is most frequently detected by immunohistochemistry 
using antibodies to viral proteins expressed in the cytoplasm 
and cellular membrane, namely latent membrane protein 
(LMP) and EB nuclear antigen (EBNA) (7).
However, the standard procedure of EBV diagnosis has 
been EBV-encoded RNA (EBER) detection by RNA in situ 
hybridization (RNA-ISH) in tumor tissue. EBER is consistently 
and highly expressed in latent infection and its detection has 
a high diagnostic sensitivity for EBV-positive lymphomas (8). 
PCR-based techniques of genomic isolates obtained from 
tumor tissue substitutes RNA-ISH with similar sensitivity and 
specificity and are also useful for strain determination in EBV 
types 1 or 2 (9).
Few studies have investigated EBV tumoral detection 
and prognosis in DLBCL. Three published studies, from 
Japanese, Peruvian and Korean populations with patient 
survival analyses, demonstrated the prognostic value of EBV 
expression using various methods. Generally, EBV-positive 
lymphomas are associated with a worse overall survival rate 
(OS) and are independent of international prognostic index 
(IPI) scores (7,10,11). Another study, comparing the expres-
sion of LMP-1 with various biological parameters in patients 
predominantly treated with conventional chemotherapy 
without rituximab, revealed that viral protein is the most potent 
prognostic factor associated with a poor survival rate (12). 
The influence of EBV positivity on the treatment response 
of patients with DLBCL has also been evaluated. Studies 
with nodal lymphomas associate the detection of EBV with 
a worse overall response rate, and one study of extranodal 
lymphomas revealed that 3/4 cases of gastric DLBCL patients 
had poor responses (7,11,13). Data concerning the influence of 
EBV presence in the prognosis and response to treatment of 
patients with DLBCL are insufficient or incompletely explored 
and have not been evaluated regarding immune therapy with 
monoclonal antibodies.
However, it is possible to detect the EBV genome in the 
peripheral blood of healthy seropositive individuals, although 
it is usually present in extremely rare latently infected memory 
B cells. By contrast, the viral load of mononuclear blood 
cells of EBV-related lymphoproliferative diseases may be 
high (14,15). The incidence of EBV in DLBCL varies across 
the world, with Asian, Latin American and Western patients' 
positivity between 5 and 15%. In Portugal, the incidence of 
EBV detection among non-Hodgkin's lymphoma (NHL) 
patients or in the general population is not known. 
The detection of EBV proteins or genes is usually performed 
on tumoral lymphoma tissue and this determines the clinical 
prognostic impact. The search for and detection of the EBV 
genome in the blood or bone marrow mononuclear cells of 
patients with DLBCL and its correlation with prognosis has 
not been previously reported. The presence of EBV in these 
cells may be interpreted as circulating colonized tumoral cells 
or as colonized physiological memory B cells.
The present study sought to investigate the presence of the 
EBV genome in the blood or bone marrow mononuclear cells of 
patients with DLBCL, some treated with anthracycline-based 
chemotherapy alone, others treated with same type of chemo-
therapy plus rituximab. The prognosis and response according 
to the patient's type of treatment was also evaluated. 
Patients and methods
Case selection and patients samples. A total of 130 patients 
aged >18 years old and diagnosed with DLBCL in the onco-
logical services of the Portuguese public health system of 
the cities of Porto and Braga were included, regardless of 
their serological positivity for EBV. Patients with DLBCL 
were selected from a pool of 350 with various NHL histo-
logical subtypes, sequentially diagnosed and that had had bone 
marrow and/or blood collected during staging procedures. 
The Hospital Ethics Committees approved the study and all 
patients provided written informed consent.
Histological diagnosis was obtained according to the 
OMS classification (16). Samples, including blood and/or 
bone marrow aspirates, were collected from all patients. In 
121 patients, both blood and bone marrow were collected, in 
4 only bone marrow was obtained and in 5 others, only blood 
was collected. Bone marrow was preferentially used in this 
study. Mononuclear cells from blood or bone marrow were 
isolated by centrifugation on Ficoll-Hipac and obtained from 
the cell-enriched fluid retained in the interface.
Registries of clinical data included demographic variables, 
Ann Arbor staging system, ECOG Performance Status scale, 
IPI type of chemotherapy and response to treatment.
DNA preparation. Genetic material was obtained from 
isolated mononuclear cells by the following method. DNA 
was extracted using a QIAamp DNA Mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer's instructions. 
Purified DNA was eluted in 70 µl of buffer AE for elution and 
stored at -20˚C.
Virus DNA detection. The identification of EBV DNA was 
performed by the real-time quantitative PCR method, based 
on a continuous monitoring of fluorescence by an optical 
system (17). The probe was labeled by two fluorescent dyes. 
One served as a reporter on the 50 end (VIC dye; Applied 
Biosystems, Foster City, CA, USA). The emission spectrum of 
the dye was quenched by a second fluorescent dye at the 30 end 
(TAMRA; Applied Biosystems). The primer and probe 
sequences were selected from BALF5 gene codifying the 
DNA polymerase of EBV as following: forward primer, 
5'-CGGAAGCCCTCTGGACTTC-3'; reverse, 5'-CCCTGT 
TTATCCGATGGAATG-3'. A fluorogenic probe, 5'-TGTACA 
CGCACGAGAAATGCGCC-3', with a sequence localized 
between PCR primers was obtained from Applied Biosystems. 
Fluorogenic PCRs were carried out in a reaction volume 
of 25 µl in a 7300 ABIPRISM System (Applied Biosystems). 
Each real-time PCR reaction consisted of TaqMan Universal 
Mastermix (Applied Biosystems), probe (7.5 mmol/l), forward 
primer (5 mmol/l), reverse primer (5 mmol/l) and DNA solu-
tion (2.5 µl). Thermal cycling was initiated with a denaturation 
step of 50˚C for 2 min and then 95˚C for 10 min followed by 
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50 cycles of denaturation at 95˚C for 15 sec, annealing and 
extension at 60˚C for 1 min. Each plate consisted of patient 
samples in duplicate and triplicate blanks of water as a negative 
control. The calibration curve of each plate was calculated based 
on a dilution series of the TaqMan Control Human Genomic 
DNA Standard (Applied Biosystems) from 1 to 1x10-3 ng/ml 
at 10 ng/µl: 1, 0.1, 0.01, 0.001 and 0.0001 ng/ml. All data were 
analyzed using the 7300 System-SDS Software (version 1.2.3) 
Sequence Detection Software (Applied Biosystems).
Results 
Diagnostic features. A total of 130 patients diagnosed with 
DLBCL were selected for this study. The median age was 
58 years and 56% were male. In total, 127 patients were diag-
nosed as DLBC and 3 as Burkitt-like NHL. Of all the cases, 
33% were classified as extra-nodal, 8% had >1 secondary 
extra-nodal invasion, 47% had B symptoms, 45% had advanced 
stage disease (III and IV), 25.8% had an ECOG performance 
status ≥2, 53% had elevated lactate dehydrogenase (LDH) 
levels, 28.2% had IPI intermediate-high (IH) or high (H) 
and 32.7% had elevated β-2 microglobulin (B2M) levels. A 
minority of patients (30%) received cyclophosphamide, doxo-
rubicin, vincristine and prednisolone (CHOP) or an equivalent 
combination (CHOP-like) chemotherapy and 60% received 
the same chemotherapy combined with rituximab (R-CHOP) 
or R-CHOP-like. The remaining patients were treated with 
chemotherapy combinations without anthracyclines. Certain 
patients were treated before 2003, the year that rituximab was 
introduced in Portugal.
EBV detection. The EBV genome was detected in 28/130 
patients (21.5%) in blood and/or bone morrow samples. Bone 
marrow was preferably used, but for 5 patients only blood 
samples were available. In another 10, the two samples were 
tested and were accordant except one case. The characteristics 
of the EBV-negative and -positive patients are shown in Table I. 
Compared with EBV-negative patients, EBV-positive patients 
had a similar mean age (57.5 versus 59.3 years), gender, nodal or 
extra-nodal presentation, Ann Arbour staging, IPI risk factors, 
serum LDH and B2M level, response to treatment, progression-
free survival and OS. Response rate [complete response (CR) 
+ partial response (PR)] was 93.2 and 88.9% for EBV-negative 
and -positive patients, respectively (not significant). 
The global survival rate was 65% at 5 years. There was 
a significant difference at 5 years of survival in the CHOP/
CHOP-like and R-CHOP/R-CHOP-like groups, with 47.7 and 
88.6%, respectively (P=0.001). Globally there was no differ-
ence between EBV-positive and -negative cases, but when 
a Breslow test was used to compare EBV-positive patients 
treated with CHOP-like or R-CHOP-like chemotherapy, a 
trend (P=0.051) favoring R-CHOP-like was attained (Fig. 1).
Clinical variables, treatment response rate and survival was 
not significantly different in EB-positive and -negative groups 
(Table I). Fig. 1 shows the survival curves by EBV status and 
type of chemotherapy. Univariate analysis revealed that age, 
Ann Arbor stage, B symptoms, ECOG system performance 
status and LDH and serum albumin levels anticipated a 
prognostic factor value, independent of the type of treatment, 
chemotherapy with or without rituximab and EBV status 
(Table I). When considering IPI in these series, a good discrim-
ination in prognosis of the groups was observed but there was 
an asymmetrical distribution of the population, with 12% of 
patients having a score of H. Fig. 2 shows the survival curves 
for the IPI groups.
Four cases of DLBCL were diagnosed in patients with 
AIDS. AIDS diagnosis occurred between 3.5 years and 
4 months before the diagnosis of DLBCL and 3 of them were 
EBV positive Of these patients, 2 succumbed; one from an 
infectious complication during treatment and the other had 
Table I. Prognostic factors for all populations and for EVB-positive and -negative subgroups. 
Variable Frequency EVB-negative EBV-positive  P-value
n 130 102 28 
Median age (years) 57.9  57.5 59.3 
>60 years old, n (%) 65 (50) 50 (49) 15 (53.6) 0.67
Gender (male), n (%) 73 (56.2) 58 (56.9) 15 (53.6) 0.76
Primary extra-nodala 43/129 (33.3%) 34 (33.3%) 9/27 (33.3%) 1
Ann Arbor stage III/IVa 58/128 (45.3%) 48 (47.5%)  10 (37%) 0.33
B symptomsa 60/127 (47.2%) 48 (48%) 12 (44.4%) 0.74
Performance status ≥2a 32/124 (25.8%) 23 (23.7%) 9 (33.3%) 0.31
Elevated B2Ma 33/101 (32.7%) 23 (29.5%) 10 (43.5%) 0.21
Elevated LDHa 66/124 (53.2%) 48 (49%) 18 (69.2%) 0.07
IPI IH+Ha 35/124 (28.2%) 28 (28.6%) 7 (26.9%) 0.86
Treatment response ≥PRa 108/119 (90.8%) 84 (93.2%) 24 (88.9%) 0.90
Relapseda 16/74 (21.6%) 15 (26.3%) 1 (5.9%) 0.07
4-year PFSb, %  71.6 70.2 82.9 0.69
5-year survivalb, %  65.2 64.3 76.7 0.91
aMissing data; blog rank test. EBV, Epstein-Barr virus; B2M, β-2 microglobulin; LDH, lactate dehydrogenase; IPI, international prognostic 
index; IH, intermediate-high; H, high; PR, partial remission; PFS, progression-free survival.
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no response to 3 different lines of immune-chemotherapy and 
succumbed to the disease within 6 months. 
Discussion 
There is a limited number of studies investigating EBV tumoral 
detection and prognosis in DLBCL. To the best of our knowl-
edge, none of these explore the virus presence in mononuclear 
cells of the blood or bone marrow while also evaluating the 
prognostic endpoints (7,10,11). The current study evaluated the 
correlation between the EBV genome expression in mononu-
clear cells of the bone marrow or peripheral blood in patients 
with DLBCL with response to treatment and survival.
Noteworthy data have emerged from a Japanese study (7) 
that evaluated the presence of EBER in tumor tissue, comparing 
a group of EBV-positive with a group of EBV-negative 
elderly DLBCL patients. A shorter survival was observed 
in EBV-positive patients with a median OS of 24 months 
versus OS not reached in EBV-negative patients, which was 
a prognostic factor independent of IPI scores. Similar results 
have been reported in a Peruvian population (10) treated 
with chemotherapy without rituximab with an OS of 7 and 
47 months for EBV-positive and -negative DLBCL patients, 
respectively. In this study, EBER tumoral expression and IPI 
scores were independent prognostic factors in a multivariate 
analysis. A study of Korean patients (11) treated with chemo-
therapy with only a small percentage combined with rituximab 
also demonstrated that EBV expression was associated with a 
worsened OS. This association is maintained in sub-groups 
of high IPI scores and phenotypical non-Germinal Center 
DLBCL patients. The differences between patients treated 
with a chemotherapy combination containing rituximab and 
those treated with a chemotherapy not containing rituximab 
were not analyzed, likely due to a small number of patients 
receiving this monoclonal antibody.
In a different approach, Paydas et al (12) evaluated the 
prognostic significance of biological factors correlated with 
angiogenic, anti-apoptotic, inflammatory and viral process 
in 88 DLBCL patients and determined that the expression 
of LMP-1 is the most important factor to determine the 
survival rate. Contrasting with those studies, the results of the 
current study using bone marrow and blood, but not tumoral 
tissue, revealed no significant difference in survival between 
EBV-positive and -negative patients. 
Cases of EBV-positive aggressive DLBCL have been 
described among Caucasian populations but a survival anal-
ysis has not been reported (18,19). We observed a case with 
an especially aggressive course in a patient co-infected with 
EBV and HIV. 
The influence of EBV positivity in treatment response 
on patients with DLBCL has been evaluated by a limited 
number of studies. Oyama et al compared 62 EBV-positive 
Japanese patients treated with anthracycline-containing regi-
mens without rituximab with 104 EBV-negative patients and 
observed overall response rates of 80 and 99%, respectively 
(P<0.0001) with CR rates of 66 and 91% (7). Park et al reported 
an overall response rate but not a complete remission rate of 
25 EBV-positive and 207 EBV-negative patients; the authors 
identified a significant difference of 72 and 92%, respec-
tively (11). In a gastric DLBCL study, 4 EBV-positive patients 
had a poor response to chemotherapy and radiotherapy with 2 
of those presenting with progressive disease, one partial and 
one complete remission (13). 
The search for EBV presence in mononuclear cells in 
bone morrow and/or blood and the evaluation of its value 
Figure 1. Survival probability according to EBV status and type of treatment. 
(A) Kaplan-Meier overall survival for patients treated with anthracycline 
or anthracenedione chemotherapy without the anti-CD20 monoclonal anti-
body rituximab. (B) Kaplan-Meier overall survival for patients treated with 
antracycline- or anthracenedione-containing chemotherapy with rituximab. 
The difference suggests that the combination of rituximab and standard 
CHOP therapy overcomes a worse prognosis induced by EBV presence on 
the B cells of patients with DLBCL. OS, overall survival; DLBCL, diffuse 
large B-cell lymphoma; EBV, Epstein-Barr virus; CHOP, cyclophosphamide, 
doxorubicin, vincristine and prednisolone; R-CHOP, CHOP with rituximab.
Figure 2: Kaplan-Meier OS curves. Outcome according to the IPI groups. 
Relative frequency predominance in low risk group may be due to a predomi-
nance of localized Ann Arbour stages and a younger median age. OS, overall 
survival; IPI, international prognostic index.
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as a prognostic tool has not been systematically performed. 
In a Brazilian study of children with Burkitt's lymphoma 
comparing different methods of EBV detection, only 9 cases 
were simultaneousely tested in tumor mass samples and bone 
marrow (9). The authors searched clonal lymphoma cells by 
immunoglobulin H gene rearrangement. They found that 
only EBV-tumor cell-positive cases with bone marrow clonal 
infiltrating cells were also EBV-positive. However, risk factors 
were not evaluated in this study.
The present study was conducted on blood and bone marrow 
searching for the presence of EBV in the mononuclear cells of 
these tissues and aimed to evaluate the prognostic relevance of 
the virus in patients with DLBCL. With a sensitive technology 
such as PCR it was possible to detect EBV-positive memory 
cells, non-tumoral lymphocytes and true malignant lympho-
cytes. However, the frequency of colonized cells in peripheral 
blood is very rare in healthy seropositive individuals, with an 
count under 1/50,000 in the majority of studies (14,15). These 
findings were the basis of the present study.
When comparing the results of the present study using 
bone marrow/blood samples with studies performed elsewhere 
that used tumor tissue cells, the frequency of detection is not 
substantially different, with 21.5 and 5-15%, respectively. 
This frequency is higher than that published for the western 
population, but it included 4 cases of HIV-positive patients. 
This result also indicates that searching in bone marrow or 
blood mononuclear cells may be a reliable method of EBV 
detection. However, it cannot distinguish tumor B cells from 
the rare EBV-colonized memory B cells, either in circulation 
or in bone marrow. Therefore, we plan to search for EBV on 
tissue cells and to compare the results between bone marrow 
and blood in the same patient. 
In contrast to the results of others, the negative prognostic 
impact usually observed in DLBCL has not been verified in 
the current study. This may be explained by the introduction of 
rituximab in therapeutic armamentarium to B-cell NHL. The 
majority of patients received R-CHOP and some were admin-
istered dose-densified R-CHOP-14, which had not occurred 
in the majority of the patients in previous studies. In fact, 
the prognostic influence of EBV presence in the rituximab 
era remains unknown. The addition of rituximab to CHOP 
chemotherapy may overcome the prognostis of Bcl2 expres-
sion on DLBCL in patients treated with CHOP and an identical 
influence may be possible on EBV expression (20). Favoring 
this hypothesis is the efficacy of rituximab in post-transplant 
lymphoproliferative disease, a syndrome typically associated 
with EBV and immunodepression (21). The current study also 
supports the favorable influence of rituximab, given that when 
CHOP-like versus R-CHOP-like patients were analyzed, the 
trend of a decreased survival rate in EBV-positive patients 
was only observed in the first group, whose treatment did not 
include rituximab. 
In conclusion, this study demonstrated the presence of 
a high percentage of EBV in mononuclear cells from bone 
marrow aspirates or the peripheral blood of patients with 
DLBCL. Detection of the virus genome was not associated 
with any clinical variable, response rate or survival rate, 
regardless of treatment, but the majority of patients in this 
study received chemotherapy and rituximab. Moreover, we 
provide evidence to support the use of rituximab in addition to 
conventional chemotherapy to improve the clinical outcomes 
associated with EBV detection in DLBCL.
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